Showing results (61-70 of 86) with videos related to
Sort By:
Pageof 9
Journal of Cancer Research and Clinical Oncology|May 7, 2024
KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathwayMeng Zhai, Jiyu Miao, Ru Zhang, et al.Frontiers in Immunology|June 13, 2025
Dynamic alterations of circulating lymphocytes during the trajectory of Hantaan virus-induced hemorrhagic fever with renal syndromeLin Su, Shuangjuan Liu, Lei Shi, et al.Cancer Immunology, Immunotherapy : CII|January 11, 2020
The CD38<sup>low</sup> natural killer cell line KHYG1 transiently expressing CD16<sup>F158V</sup> in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricideSubhashis Sarkar, Sachin K S Chauhan, John Daly, et al.Nature Communications|November 9, 2013
Probing single- to multi-cell level charge transport in Geobacter sulfurreducens DL-1Xiaocheng Jiang, Jinsong Hu, Emily R Petersen, et al.Nature Communications|July 20, 2018
Manipulation of facet orientation in hybrid perovskite polycrystalline films by cation cascadeGuanhaojie Zheng, Cheng Zhu, Jingyuan Ma, et al.Journal of Cellular and Molecular Medicine|September 1, 2020
The phenotypic changes of γδ T cells in COVID-19 patientsLei Lei, Hongbo Qian, Xiaofang Yang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
CD167 acts as a novel costimulatory receptor in T-cell activationNana Dang, Jinsong Hu, Xinping Liu, et al.Cell Stress & Chaperones|February 7, 2020
Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myelomaLingjuan Huang, Yanmeng Wang, Ju Bai, et al.Journal of Cellular and Molecular Medicine|September 25, 2020
Naturally activated adaptive immunity in COVID-19 patientsXiaofeng Yang, Tongxin Dai, Xiaobo Zhou, et al.Blood|June 10, 2010
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrugJinsong Hu, Damian R Handisides, Els Van Valckenborgh, et al.Pageof 9